KIF14 mediates cabazitaxel-docetaxel cross-resistance in advanced prostate cancer by promoting AKT phosphorylation.

[1]  A. Jemal,et al.  Cancer statistics, 2022 , 2022, CA: a cancer journal for clinicians.

[2]  Huiyong Shen,et al.  ZIP10 drives osteosarcoma proliferation and chemoresistance through ITGA10-mediated activation of the PI3K/AKT pathway , 2021, Journal of experimental & clinical cancer research : CR.

[3]  S. Egawa,et al.  Abiraterone acetate versus nonsteroidal antiandrogen with androgen deprivation therapy for high‐risk metastatic hormone‐sensitive prostate cancer , 2021, The Prostate.

[4]  D. Grzanka,et al.  Prognostic Impact and Functional Annotations of KIF11 and KIF14 Expression in Patients with Colorectal Cancer , 2021, International journal of molecular sciences.

[5]  M. Mapundu,et al.  Using text mining techniques to extract prostate cancer predictive information (Gleason score) from semi-structured narrative laboratory reports in the Gauteng province, South Africa , 2021, BMC Medical Informatics and Decision Making.

[6]  R. Mathijssen,et al.  Cross-resistance and drug sequence in prostate cancer. , 2021, Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy.

[7]  Y. Assaraf,et al.  Taxanes in cancer treatment: Activity, chemoresistance and its overcoming. , 2021, Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy.

[8]  A. Asenjo,et al.  Structural basis of mechano-chemical coupling by the mitotic kinesin KIF14 , 2020, Nature Communications.

[9]  Hui Liu,et al.  KIF15-Mediated Stabilization of AR and AR-V7 Contributes to Enzalutamide Resistance in Prostate Cancer , 2020, Cancer Research.

[10]  Xing Wu,et al.  KIF14 and KIF23 Promote Cell Proliferation and Chemoresistance in HCC Cells, and Predict Worse Prognosis of Patients with HCC , 2020, Cancer management and research.

[11]  M. Rizzo.  Mechanisms of docetaxel resistance in prostate cancer: the key role played by miRNAs. , 2020, Biochimica et biophysica acta. Reviews on cancer.

[12]  B. Zhai,et al.  Silencing KIF14 reverses acquired resistance to sorafenib in hepatocellular carcinoma , 2020, Aging.

[13]  Qingwei Zhao,et al.  Establishment and characterization of a docetaxel-resistant human prostate cancer cell line , 2020, Oncology letters.

[14]  Yurong Song,et al.  PI3K/AKT pathway as a key link modulates the multidrug resistance of cancers , 2020, Cell Death & Disease.

[15]  N. Agarwal,et al.  Advanced Prostate Cancer: Treatment Advances and Future Directions. , 2020, Trends in cancer.

[16]  Iftikhar Ali,et al.  The functions of kinesin and kinesin-related proteins in eukaryotes , 2020, Cell adhesion & migration.

[17]  Q. Cao,et al.  Targeting the KIF4A/AR Axis to Reverse Endocrine Therapy Resistance in Castration-resistant Prostate Cancer , 2019, Clinical Cancer Research.

[18]  Tetsutaro Hayashi,et al.  TUBB3 Reverses Resistance to Docetaxel and Cabazitaxel in Prostate Cancer , 2019, International journal of molecular sciences.

[19]  Zemin Zhang,et al.  GEPIA2: an enhanced web server for large-scale expression profiling and interactive analysis , 2019, Nucleic Acids Res..

[20]  Yingli Wu,et al.  KIF14 promotes tumor progression and metastasis and is an independent predictor of poor prognosis in human gastric cancer. , 2019, Biochimica et biophysica acta. Molecular basis of disease.

[21]  P. Wadsworth,et al.  Kinesin-5 Regulation and Function in Mitosis. , 2019, Trends in cell biology.

[22]  G. Yip,et al.  Kinesin superfamily: roles in breast cancer, patient prognosis and therapeutics , 2018, Oncogene.

[23]  F. Saad,et al.  Cabazitaxel Versus Docetaxel As First-Line Therapy for Patients With Metastatic Castration-Resistant Prostate Cancer: A Randomized Phase III Trial-FIRSTANA. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[24]  Chad J. Creighton,et al.  UALCAN: A Portal for Facilitating Tumor Subgroup Gene Expression and Survival Analyses , 2017, Neoplasia.

[25]  V. Cucchiara*,et al.  ABCB1 Mediates Cabazitaxel–Docetaxel Cross-Resistance in Advanced Prostate Cancer , 2017, Molecular Cancer Therapeutics.

[26]  H. Ng,et al.  The kinesin KIF14 is overexpressed in medulloblastoma and downregulation of KIF14 suppressed tumor proliferation and induced apoptosis. , 2017, Laboratory investigation; a journal of technical methods and pathology.

[27]  Ji-Young Hong,et al.  Paclitaxel-resistant cancer cell-derived secretomes elicit ABCB1-associated docetaxel cross-resistance and escape from apoptosis through FOXO3a-driven glycolytic regulation , 2017, Experimental & Molecular Medicine.

[28]  Yanhua Shi,et al.  Up-regulation of KIF14 is a predictor of poor survival and a novel prognostic biomarker of chemoresistance to paclitaxel treatment in cervical cancer , 2016, Bioscience reports.

[29]  Steven L Salzberg,et al.  HISAT: a fast spliced aligner with low memory requirements , 2015, Nature Methods.

[30]  A. Asenjo,et al.  KIF14 binds tightly to microtubules and adopts a rigor-like conformation. , 2014, Journal of molecular biology.

[31]  Paul Theodor Pyl,et al.  HTSeq—a Python framework to work with high-throughput sequencing data , 2014, bioRxiv.

[32]  Björn Usadel,et al.  Trimmomatic: a flexible trimmer for Illumina sequence data , 2014, Bioinform..

[33]  L. Lum,et al.  KIF14 promotes AKT phosphorylation and contributes to chemoresistance in triple-negative breast cancer. , 2014, Neoplasia.

[34]  G. Pond,et al.  Potential value of Gleason score in predicting the benefit of cabazitaxel in metastatic castration-resistant prostate cancer. , 2013, Future oncology.

[35]  Davis J. McCarthy,et al.  Count-based differential expression analysis of RNA sequencing data using R and Bioconductor , 2013, Nature Protocols.

[36]  J. Herman,et al.  The Epigenetic promise for prostate cancer diagnosis , 2012, The Prostate.

[37]  Oliver Rath,et al.  Kinesins and cancer , 2012, Nature Reviews Cancer.

[38]  J. Liao,et al.  MK-2206, a Novel Allosteric Inhibitor of Akt, Synergizes with Gefitinib against Malignant Glioma via Modulating Both Autophagy and Apoptosis , 2011, Molecular Cancer Therapeutics.

[39]  A. Belldegrun,et al.  Novel therapeutic strategies for castration resistant prostate cancer: inhibition of persistent androgen production and androgen receptor mediated signaling. , 2011, The Journal of urology.

[40]  J. Machiels,et al.  Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial , 2010, The Lancet.

[41]  I. Tannock,et al.  A Contemporary Prognostic Nomogram for Men with Hormone-Refractory Metastatic Prostate Cancer: A TAX327 Study Analysis , 2007, Clinical Cancer Research.

[42]  Michael W Kattan,et al.  Defining biochemical recurrence of prostate cancer after radical prostatectomy: a proposal for a standardized definition. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[43]  Erich A. Nigg,et al.  KIF14 and citron kinase act together to promote efficient cytokinesis , 2006, The Journal of cell biology.

[44]  P. Kantoff,et al.  Prognostic model for predicting survival in men with hormone-refractory metastatic prostate cancer. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.